60 Degrees Pharmaceuticals, Inc. (SXTP)

0.2820 +0.0070 (+2.55%) At close: 04:00PM EDT

60 Degrees Pharmaceuticals, Inc.

1025 Connecticut Avenue NW
Suite 1000
Washington, DC 20036
United States
202-327-5422
https://www.60degreespharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 3

Description

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.

Corporate governance

60 Degrees Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.